摘要
目的探讨晚期非小细胞肺癌(NSCLC)患者接受吉非替尼治疗前后血清肿瘤标记物癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角质蛋白-19片断抗原(Cyfra21-1)以及神经元特异性烯醇化酶(NSE)水平变化及意义。方法应用化学发光法检测40例临床IIIB～IV期NSCLC患者经过3个月的吉非替尼治疗前后血清CEA、CA125、Cyfra21-1以及NSE水平的变化,并根据治疗前后肺部CT影像学改变进行分析。结果吉非替尼治疗后控制组CEA、CA125水平较治疗前显著降低(P<0.05),未控制组则显著升高(P<0.05);血清Cyfra21-1及NSE水平治疗前后比较均无统计学意义(P>0.05)。治疗前CEA升高的比例在两组之间存在统计学意义(P<0.05)。结论监测血清肿瘤标记物水平有助于判断吉非替尼治疗晚期NSCLC患者的临床疗效,治疗前血清CEA的水平对疗效有预测作用,具有一定的临床价值。
Objective To investigate the value of md NSE in evaluating therapeutic effect of Gefitinib the changes of tumor markers CEA,GA123,C;YPIKAZI-I in advanced NSCLC patients. Methods The serum levels of 2EA,CA125 ,Cyfra21-1 and NSE in 40 patients with Stage I]IB--IV NSCLC given 3 months＇ treatment of Gefitinib by chemiluminescence method were detected, and the efficacy was compared by the changes in CT of the ungs. Results The serum CEA and CA125 levels in the controlled patients treated by Gefitinib were significantly ower than those before treatment （ P 〈 0.05） and increased significantly in the unconcholled patients （ P 〈 ）. 05）. The serum Cyfra21-1 and NSE levels had no statistical significance before and after treatment （ P 〉 0. ）5）. By comparing the serum levels of tumor markers in the two groups before and after treatment, we found -hat the change of the serum CEA level in different group had statistical significance （ P ＂〈 0.05 ）. ConclusionTo detect the serum tumor markers can help to evaluate the therapeutic effect of Gefitinib for advanced NSCLS patients, which has some clinical value. And the level of CEA before treatment can be used as an indicator to predict the efficacy of Gefitinib.
出处
《山东医学高等专科学校学报》
2011年第2期91-93,共3页
Journal of Shandong Medical College
